ABSTRACT

Zika Virus (ZIKV) is promptly spreading across the America and its disastrous outcomes for pregnant women and infants have driven this earlier ignored pathogen into the eminence. Clinical Symptoms are fever, joint pain or rash and conjunctivitis. The Zika virus (ZIKV), first discovered in 1947, has emerged as a global public health threat over the last decade, with the accelerated geographic spread of the virus noted during the last 5 years. The first outbreak of ZIKV has been reported in the Pacific area in 2007, followed by the second large outbreak in 2013/2014 and subsequently the virus broaden in other Pacific islands. DNA vaccine, recombinant subunit vaccine, ZIKV purified inactivated vaccine, and chimeric vaccines of various such vaccine platforms have shown robustic effect in vitro and in vivo trials. Numeral drugs such as Sofosbuvir, BCX4450, NITD008 and 7-DMA are ready to set foot in phase-I clinical trial because of approved anti-ZIKV activity. Monoclonal based antibodies had shown a promising result in pregnant women. Without further knowledge of the pathophysiology involved the true risk of ZIKV to the unborn remains difficult to evaluate and remediate. Accurate, portable, and inexpensive point-of-care testing is required to better identify cases and manage the current and future outbreaks of ZIKV, including optimization of preventive approaches and the identification of more effective risk reduction strategies. In addition, much more work needs to be done to produce an effective vaccine. Given the rapid geographic spread of ZIKV in recent years, a coordinated local, regional, and global effort is needed to generate sufficient resources and political traction to effectively halt and contain further expansion of the current outbreak. Keywords: Zika Virus, Emergence, Prevention, In vitro and In vivo Models
Publication date: 01/03/2023

https://ijbpas.com/pdf/2023/March/MS_IJBPAS_2023_6987.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.3.6987